Drug Profile
PRAX 114
Alternative Names: PRAX-114Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Praxis Precision Medicines
- Class Antidepressants; Antiepileptic drugs; Antipsychotics
- Mechanism of Action GABA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Major depressive disorder
- Phase II Essential tremor
- No development reported Depressive disorders; Epilepsy
- Discontinued Post-traumatic stress disorders
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for phase-I development in Depressive disorders(In volunteers) in Australia (PO, Suspension)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Depressive disorders(In volunteers) in Australia (PO, Tablet)
- 12 Dec 2022 Discontinued - Phase-II for Post-traumatic stress disorders in USA (PO) (Praxis Precision Medicines pipeline, December 2022)